Skip to main content
    S

    Sophia Genetics SA (SOPH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $7.44
    -0.77 (-9.38%)

    Market Cap: $703.25M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sophia Genetics SA (SOPH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Sophia Genetics SA reported revenue of $77.27M for the fiscal year ended Dec 31, 2025, up 18.6% from the year before. That year, net income was -$79.00M with a net margin of -102.2%, operating cash flow was -$38.01M and free cash flow was -$38.59M. The quarter ended Sep 30, 2026 had revenue of $24.27M and net income of -$20.27M.

    Revenue and Margins

    The operating margin was -91.8% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $25.36M, a compound annual rate of 20.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$77.27M+18.6%61.9%-91.8%-102.2%
    Dec 2024$65.17M+4.5%67.4%-102.1%-95.9%
    Dec 2023$62.37M+31.1%68.8%-120.0%-126.6%
    Dec 2022$47.56M+17.6%65.7%-184.7%-183.9%
    Dec 2021$40.45M+42.4%62.4%-176.7%-182.1%
    Dec 2020$28.40M+12.0%62.3%-131.6%-138.5%
    Dec 2019$25.36MN/A70.3%-127.3%-133.2%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$77.27M$65.17M$62.37M$47.56M$40.45M$28.40M$25.36M
    Cost of revenue$29.46M$21.24M$19.46M$16.31M$15.23M$10.71M$7.53M
    Gross profit$47.81M$43.94M$42.91M$31.25M$25.22M$17.69M$17.83M
    Research and development$33.57M$34.37M$36.97M$35.37M$26.58M$18.59M$15.02M
    Operating income-$70.92M-$66.57M-$74.83M-$87.82M-$71.49M-$37.39M-$32.29M
    Net income-$79.00M-$62.49M-$78.98M-$87.45M-$73.67M-$39.34M-$33.79M
    EBITDA-$64.40M-$50.76M-$69.57M-$81.38M-$69.24MN/A-$30.74M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$24.27M$23.31M$21.69M$21.71M$19.46M$18.32M$17.78M$17.73M$15.85M$15.81M$15.78M$17.05M
    Gross profit$15.93M$15.06M$14.75M$14.69M$12.91M$12.27M$12.21M$12.10M$10.65M$10.78M$10.40M$11.90M
    Operating income-$17.82M-$20.05M-$17.28M-$18.05M-$17.86M-$18.56M-$16.04M-$17.44M-$15.36M-$15.01M-$18.76M-$18.95M
    Net income-$20.27M-$22.36M-$19.32M-$19.18M-$20.02M-$22.41M-$17.39M-$15.16M-$18.44M-$15.19M-$13.70M-$24.06M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $50.43M by $19.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$163.46M$155.31M$206.16M$243.84M$320.17M$132.12M$51.66M$76.62M
    Current assets$99.08M$99.41M$148.05M$196.25M$282.86M$109.69M$33.76M$62.72M
    Cash and equivalents$70.29M$80.23M$123.25M$161.31M$192.96M$74.63M$18.07M$53.91M
    Total liabilities$116.31M$58.82M$54.71M$43.71M$44.77M$31.61M$29.40M$21.80M
    Short-term debt$2.70M$2.19M$2.93M$2.69M$1.81M$3.91M$3.19M$2.49M
    Long-term debt$47.73M$13.24MN/AN/AN/A$457.00K$1.61M$3.91M
    Shareholder equity$47.15M$96.49M$151.44M$200.13M$275.40M$100.51M$22.25M$54.82M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$184.73M$198.36M$157.00M$163.03M$163.46M$177.62M$146.72M$155.31M$177.61M$181.10M$180.26M$206.16M
    Total liabilities$116.30M$115.24M$111.31M$115.89M$102.77M$100.93M$61.11M$58.82M$64.10M$59.65M$48.03M$54.71M
    Cash and equivalents$93.65M$107.67M$65.39M$70.29M$81.61M$94.82M$68.53M$80.23M$95.79M$105.40M$103.73M$123.25M
    Shareholder equity$68.43M$83.12M$45.69M$47.15M$60.69M$76.69M$85.61M$96.49M$113.51M$121.44M$132.23M$151.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$38.01M-$42.82M-$48.58M-$70.09M-$57.94M-$31.73M-$31.68M
    Capital expenditures$574.00K$8.18M$9.23M$10.38M$6.67M$3.20M$3.03M
    Free cash flow-$38.59M-$51.00M-$57.80M-$80.47M-$64.61M-$34.93M-$34.71M
    Investing cash flow-$10.51M-$8.18M$8.32M$41.97M-$56.93M-$24.32M-$3.03M
    Financing cash flow$34.13M$11.59M-$2.82M-$1.57M$237.77M$107.05M-$1.02M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$9.48M-$7.69M-$16.18M-$8.94M-$8.79M-$8.21M-$10.75M-$10.60M-$7.16M-$10.42M-$14.64M-$11.29M
    Capital expenditures$2.32M$2.70M$878.00K$348.42K$106.00K$1.98M$1.49M$1.94M$2.32M$1.96M$1.96M$2.25M
    Free cash flow-$11.79M-$10.39M-$17.06M-$9.28M-$8.90M-$10.19M-$12.24M-$12.54M-$9.48M-$12.37M-$16.60M-$13.54M
    Last 12 quarters

    Frequently Asked Questions About SOPH

    What is Sophia Genetics SA's annual revenue?

    Sophia Genetics SA reported revenue of $77.27M for the fiscal year ended Dec 31, 2025.

    How fast is Sophia Genetics SA's revenue growing?

    Revenue was up 18.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.6%.

    Is Sophia Genetics SA profitable?

    No. Sophia Genetics SA reported net income of -$79.00M for the fiscal year ended Dec 31, 2025, with a net margin of -102.2%.

    How much free cash flow does SOPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$38.01M minus capital expenditures of $574.00K produced free cash flow of -$38.59M.

    How much debt does Sophia Genetics SA have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $47.73M, short-term debt of $2.70M and cash and equivalents of $70.29M.